LIAN - LianBio soars 11% as mavacamten gets breakthrough therapy status in China

LianBio (NASDAQ:LIAN) said the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted breakthrough therapy designation in China for mavacamten to treat patients with obstructive hypertrophic cardiomyopathy (oHCM). Hypertrophic cardiomyopathy is a condition in which the heart muscle becomes abnormally thick which can make it harder for the heart to pump blood. The designation was backed by data from a global phase 3 EXPLORER-HCM trial of mavacamten in oHCM patients with New York Heart Association (NYHA) class II–III symptoms. In the study mavacamten met all primary and secondary goals with statistical significance and showed clinically meaningful improvement in functional status, symptoms, and quality of life. LIAN +11.40% premarket to $4.3

For further details see:

LianBio soars 11% as mavacamten gets breakthrough therapy status in China